Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI is equally capable of reading breast cancer scans as human radiologists.

2.

Breast cancer: A new target to eliminate dormant cells before they wake

3.

In cases of metastatic or recurrent head and neck cancer, gene-guided immunotherapy falls short.

4.

Real World CAR T-Cell Therapy Outcomes 'Favorable' in Relapsed/Refractory Myeloma

5.

Sickle Cell Disease Drug Pulled From Global Markets


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot